FIGURE 4.
(A,B,D–F) Correlation between abnormal amygdala RSFC at baseline and the remission rate of depressive symptoms and suicidal symptoms after ketamine treatment and ROC curve analysis. (C) Neuroimaging predictors of treatment non-response, with the non-responders defined with <50% improvements in HAMD-17 obtained after the ketamine infusions. The area under the ROC curve was 0.689 (p = 0.043) for the RSFC of the LA – right putamen, with a sensitivity of 91.4%, and specificity of 59.1%; the area under the ROC curve was 0.726 (p = 0.016) for RA – right putamen connectivity, with a sensitivity of 82.4%, and specificity of 68.2%; and the area under the ROC curve was 0.739 (p = 0.011) for LA – right putamen connectivity and RA-right putamen connectivity, with a sensitivity of 75.0%, and specificity of 73.7%. (G) Non-responders defined with <50% improvements SSI-5 score obtained after the ketamine infusions. The area under the ROC curve was 0.799 (p = 0.003) for the RSFC of the LA – right putamen, with a sensitivity of 77.8%, and specificity of 83.3%; the area under the ROC curve was 0.787 (p = 0.005) for the RA – right putamen connectivity, with a sensitivity of 59.3%, and specificity of 91.7%; and the area under the ROC curve was 0.827 (p = 0.001) for LA – right putamen connectivity and RA – right putamen connectivity, with a sensitivity of 74.1%, and specificity of 83.3%. AUC, area under curve; LA, left amygdala; RA, right amygdala.